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E-mail address: rpebstein@gmail.com (R.P. EbsteinIncreasing evidence suggests that the nonapeptide, oxytocin (OT), helps shape social and afﬁliative
behaviors not only in lower mammals but also in humans. Recently, an essential mediator of brain
OT release has been discovered, ADP-ribosyl cyclase and/or CD38. We have subsequently shown that
polymorphisms across the CD38 gene are associated with autism spectrum disorders (ASD). Notably,
CD38 expression in lymphoblastoid cells (LBC) is reduced in cell lines derived from ASD subjects
compared to parental cell lines. Intriguingly, a correlation was observed between CD38 expression
and measures of social function in ASD. Finally, we have shown that all-trans retinoic acid (ATRA),
a known inducer of CD38 transcription, can rescue low CD38 expressing LBC lines derived from ASD
subjects and restore normal levels of transcription of this ectoenzyme providing ‘proof of principle’
in a peripheral model that retinoids are potential therapeutic agents in ASD.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Oxytocin
Classically, the nonapeptide oxytocin (OT) has been viewed as a
hypothalamic neuropeptide that is released into the general circu-
lation from the neural lobe of the pituitary, inducing uterine con-
tractions during parturition and milk ejection during lactation.
OT is derived from a pre-prohormone precursor that is synthesized
in the hypothalamus and stored in vesicles at the posterior pitui-
tary for storage and subsequent release into the bloodstream (see
[1] for comprehensive review of the oxytocin receptor system).
2. OT and social behavior
Beyond the long-known peripheral effects of OT, a wealth of
animal studies have elaborated the role of OT, or their analogues
such as isotocin and vasotocin [2], in molding social behavior from
ﬁsh to mammals [3]. In the past few years the role of OT has also
been examined in our own species, and similar to what has been
learned from animal studies, it appears that this nonapeptides alsochemical Societies. Published by E
artment, Faculty of Arts and
ity of Singapore, Singapore
).inﬂuence social behaviors in humans [4,5]. Indeed, OT has been
suggested as the ‘great facilitator of life’ in a recent review [6].
In humans, intranasal administration of OT has been shown to
increase trust [7], facilitate mind-reading [8], enhance human
memory for social identity [9], increase positive communication
between couples [10], increase gaze to the eye region [11] and in-
crease generosity [12]. Intriguingly, OT plasma levels have been
linked to individual patterns of maternal-fetal attachment [13]
and salivary OT levels were associated with bonding to own par-
ents and inversely related to psychological distress, particularly
depressive symptoms [14]. Social anxiety symptom severity, ad-
justed for age and gender in a healthy group of subjects, was asso-
ciated with higher plasma oxytocin levels [15]. Imaging studies
reinforce the role of OT in inﬂuencing human social behavior with
evidence demonstrating that OT modulates the amygdala and
other brain regions [16].3. Oxytocin receptor gene (OXTR)
The OT receptor gene is present in single copy in the haploid hu-
man genome and was mapped to the gene locus 3p25–3p26.2 [1].
The gene spans 17 kb and contains 3 introns and 4 exons. Exons 1
and 2 correspond to the 50 non-coding region. Exons 3 and 4 encode
the amino acids of the OT receptor. Intron 3, which is the largest atlsevier B.V. All rights reserved.
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transmembrane domain 6. Exon 4 contains the sequence encoding
the seventh transmembrane domain, the COOH terminus, and the
entire 3’-non-coding region, including the polyadenylation signals.
The OT receptor protein is a typical member of the rhodopsin-type
(class I) G protein class of receptors (GPCR) family [1]. The seven
transmembrane-helices aremost highly conserved among theGPCR
family members. Conserved residues among the GPCRs may be in-
volved in a commonmechanism for activation and signal transduc-
tion to the G protein. The OT receptor signals via the Gq/11 and Gi
class of guanosine triphosphate (GTP) binding proteins that stimu-
late, together with Gbx, the phospholipase C-b isoforms [17]. The
selectivity of theOT receptor forG-proteins appears tobemore com-
plex than the selectivity of the vasopressin receptors. Coexpression
of different combinations of intracellular domains demonstrates
that all intracellular loops may contribute to the selectivity of the
OT receptor to some extent. In addition to the intracellular domains,
ahighly conserved regionof theC-terminaldomain is involved in the
selectivity of coupling to Gq/11 but not Gi.
4. Oxytocin and autism spectrum disorders (ASD)
Autistic disorders (AD) are a group of disorders characterized by
the three core deﬁcits: qualitative impairment in social interaction
and communication, and restricted repetitive and stereotyped pat-
terns of behavior, interests, and activities [18]. The three disorders
autism, Asperger syndrome (AS) and pervasive developmental dis-
order-not otherwise speciﬁed (PDD-NOS) are currently thought of
by most researchers as a continuum of the same disorder with
varying degrees of severity, associated intellectual functioning
and medical conditions. Recent studies estimated the prevalence
of AD to around 0.5–1% [19]. Genetic factors play an important role
in ASD [20].
A number of molecular genetic ﬁndings support the involve-
ment of oxytocin neurotransmission in some of the social deﬁcits
and symptomatology of ASD. Firstly, signiﬁcant association be-
tween OXTR SNPs [21–26] and risk for autism has been provision-
ally shown (but also see [27,28]) and, notably, was mediated by
socialization skills in our study [23]. Additionally, SNPs associated
with ASD are also associated with amygdala volume [29], depres-
sion/anxiety [29], negative emotionality [30], attention deﬁcit
[31], adult attachment styles [32,33] (but see[34]), affectivity,
emotional loneliness and IQ [35], empathy and stress reactivity
[36], observed parenting [37], with sexual phenotypes [38] and
in our own studies with prosocial behavior [39]. Interestingly,
the AVPR1a receptor of the closely related nonapeptide vasopres-
sin has also been associated with ASD [40–42]. This provisional
role of OT in ASD, is further supported by two linkage studies
[43,44], clinical evidence by several groups demonstrating clinical
improvement in ASD following OT administration [45–51] (also see
[52,53]) and studies showing that ASD is also associated with alter-
ations in OT plasma levels [54].
5. Dendritic release of oxytocin
An interesting feature of OT action in the brain is that although
OT has profound effects on social bonding that are exerted at sites
that richly express oxytocin receptors, such brain regions are
innervated by few, if any, oxytocin-containing projections [55].
How then does OT exert its effect in limbic and other ‘socially sen-
sitive’ brain regions in the absence of apparent direct OT contain-
ing neurons? Oxytocin synthesis takes place in hypothalamic
nuclei, including the supraoptic nucleus (SON) and paraventricular
nucleus (PVN). Speciﬁcally, magnocellular neurons in these two
nuclei contain most of the OT and AVP in the CNS and arecharacterized by dendritic release, which is regulated indepen-
dently of secretion into the blood. Indeed, dendrites are apparently
the major source of peptides released in the brain [55]. Importantly
dendritic release does not parallel axonal release and both pro-
cesses are regulated independently. Although release of OT and
AVP from axons is linked to electrical activity resulting from
Ca2+ entry through voltage-gated ion channels following depolar-
ization of the terminals by invading action potentials [56], OT and
AVP themselves [57], can elicit dendritic peptide release without
increasing electrical activity. In OT neurons, OT itself mobilizes
Ca2+ from thapsigargin-sensitive intracellular stores [58]. Activa-
tion of peptide receptors on the dendrites or soma elevates intra-
cellular Ca2+ concentrations and triggers exocytosis of large
dense-core vesicles (LDCVs), and once dendritic peptide release is
triggered, because of the peptide feedback, dendritic release can
be self-sustaining and, therefore, long-lasting.
6. CD38
A seminal paper by Higashida and his group led to the discovery
that OT release in the brain is mediated by ADP-ribosyl cyclase
and/or CD38 [59]. They used CD38 gene knockout mice (Cd38/
), and discovered that CD38-dependent cyclic ADP ribose (cAD-
PR)- and NAADP-sensitive intracellular Ca2+ mobilization plays a
key role in OT release from soma and axon terminals of hypotha-
lamic neurons, with marked effects on social behavior. In particu-
lar, maternal behavior was dependent on OT, and social amnesia in
males was evident in the absence of this hormone. Activation of
CD38 with its substrate ligand NAD+ results in hydrolysis of
NAD+ and cyclic ADP-ribose (cADPR) to ADP-ribose, or in cycliza-
tion of NAD+ to cADPR. In addition to production of cADPR, the en-
zyme can use NADP+ as a substrate and catalyze the exchange of
its nicotinamide group with nicotinic acid to produce NAADP+.
cADPR mobilizes Ca2+ from ryanodine-sensitive intracellular
Ca2+ stores in the endoplasmic reticulum and NAADP liberates it
from other pools located in lysosomes or secretory granules. The
two molecules act as second messengers independent of inositol
1,4,5-trisphosphate (IP3) [60,61]. To summarize, CD38 is a multi-
functional molecule (ecto-enzyme) combining enzymatic and
receptor properties and playing a key role in various physiological
processes in the tissues (proliferation, differentiation, migration,
adhesion, and secretion). In the brain, CD38 is found in neurons
and glial cells, shows intracellular or plasma membrane location,
and is enriched in neuronal perikarya and dendrites [62,63].
CD38 is critical for OT but not AVP release.
7. CD38 and autism spectrum disorders
The accumulating evidence discussed above, that OT plays an
important role in both normal as well as dysfunctional social rela-
tionships/cognition [64,65], ipso facto targets CD38, a key mediator
of OT brain release, as a potential focus of interest in normal hu-
man social behaviors as well as disorders of social cognition espe-
cially autism [66,67]. In the past year, two research groups have
independently addressed the role of CD38 in autism in human
subjects. Higashida and his colleagues [68] analyzed 10 single
nucleotide polymorphisms (SNPs) and mutations of CD38 by re-
sequencing DNAs mainly from a case–control study in Japan, and
Caucasian cases mainly recruited to the Autism Genetic Resource
Exchange (AGRE). CD38 SNPs, rs6449197 and rs3796863 showed
signiﬁcant associations with a subset of ASD subjects (IQ > 70; des-
ignated as high functioning autism/HFA) in 104 AGRE family trios,
but not with Japanese 188 HFA subjects. Interestingly, a mutation/
rare polymorphism that caused tryptophan to replace arginine at
amino acid residue 140 (R140W; (rs1800561, 4693C > T)) was
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with ASD in the smaller case–control study. The SNP was clustered
in pedigrees in which the fathers and brothers of T-allele-carrier
probands had ASD or ASD traits. In this cohort [68] OT plasma lev-
els were lower in subjects with the T allele than in those without.
In our ﬁrst study of CD38 [69], we examined all tagging SNPs
across the CD38 gene region in 170 subjects diagnosed with ASD
from 149 families (see [23] for description of the subjects). Indi-
vidual SNPs and haplotypes were tested for association with
ASD. Additionally, the relationship between diabetes, autism
and CD38 [70], as well as the use of CD38 as a disease marker
[71], suggests that it would also be worthwhile to explore
CD38 expression in immune cell lines derived from ASD patients.
These considerations prompted us to measure CD38 gene
expression in lymphoblastoid cell lines (LBC) derived from both
ASD subjects and unaffected parents. We also include in the
gene expression and family-based association analysis the SNP
(rs3796863), which proved signiﬁcantly associated with ASD in
the Munesue et al. [72] study.
8. Molecular genetic association [71]
We ﬁrst examined association between CD38 tagging SNPs and
DSM IV ASD. ASD subjects were evenly grouped into high and low
functioning based on an IQ cutoff of 70. This subject stratiﬁcation
was aimed at reducing phenotypic heterogeneity in the autism
sample. Signiﬁcant association was observed between low func-
tioning ASD and three – seven haplotypes (Table 1). The results
shown in the Table are signiﬁcant (p < 0.05) following permutation
testing. Importantly, the SNP (and the ‘C’ allele) identiﬁed in the
Munesue et al study [68] (rs3796863), which they foundTable 1
Haplotype association of CD38 SNPs with low functioning ASD subjects.
HAP Freq. Transmitted Untransmitted Chi Square p value
rs3796863-rs1803404-rs1130169
Likelihood ratio chi square = 12.14; df = 4; global p-value = 0.016 (0.019)
CTC 0.501 85.87 64.62 4.78 0.028
ATT 0.201 35.87 38.81 0.939 0.332
CTT 0.194 17.13 36.38 7.47 0.006
rs10805347–rs3796863–rs1803404–rs1130169
Likelihood ratio chi square = 20.69; df = 9; global p-value = 0.014 (0.01)
ACTC 0.316 39.97 39.24 0.005 0.938
GCTC 0.187 42.58 20.25 9.419 0.002
GATT 0.186 31.53 24.23 1.101 0.294
GCTT 0.178 16.44 31.45 4.796 0.028
rs2286553–rs10805347–rs3796863–rs1803404–rs1130169
Likelihood ratio chi square = 25.46; df = 11; global p-value = 0.008 (0.019)
GACTC 0.317 39.99 39.72 3.25e05 0.999
GGCTC 0.186 42.25 19.76 9.768 0.001
GGCTT 0.177 16.76 31.8 4.762 0.029
GGATT 0.173 28.97 24.45 0.493 0.482
rs3796864–rs2286553–rs10805347–rs3796863–rs1803404–rs1130169
Likelihood ratio chi square = 41.52; df = 13; global p-value = 7.81e05 (0.009)
CGACTC 0.313 39.99 37.76 0.075 0.783
CGGCTC 0.179 41.19 18.85 9.528 0.002
CGGCTT 0.167 15.77 29.15 3.525 0.061
AGGATT 0.125 16.95 19 0.152 0.695
rs4516711–rs3796864–rs2286553–rs10805347–rs3796863–rs1803404–
rs1130169
Likelihood ratio chi square = 34.78; df = 12; global p-value = 0.0005 (0.0049)
GCGACTC 0.297 38.99 31.84 1.006 0.315
GCGGCTC 0.180 38.16 18.97 8.064 0.004
GCGGCTT 0.162 14.84 27.03 3.808 0.051
CAGGATT 0.123 16.99 18 0.396 0.842
Global p-values are presented for each haplotype window followed by the p-values
for the individual common haplotypes (>10%). p-values in parentheses are after
permutation test. The IQ cutoff <70 was used to deﬁne the low functioning group.signiﬁcantly associated with ASD, is located in all except one of
the signiﬁcant haplotypes in our study.
9. Is CD38 expression in peripheral cells a hallmark for ASD
[69,72]?
CD38 mRNA levels in LBC derived from subjects with autism
and unaffected parents were also examined in our study (Fig. 1).
A highly signiﬁcant reduction (SPSS ANOVA-Affected status:
F = 14.72, p = 0.0002, df = 1; Sex: F = 4.680, p = 0.033, df = 1; Inter-
action: affected x sex, F = 2.304, p = 0.132, df = 1) in CD38 expres-
sion was observed in cells from the DSM IV ASD subjects (N = 44)
compared to ‘‘unaffected’’ parents (N = 40). Main effects are ob-
served for diagnosis and sex. The reduction in CD38 expression is
more marked in female ASD subjects than in male ASD subjects.
These ﬁrst results [69] have now been partially replicated in a
new study from our laboratory [72]. In the new expanded study
there was no effect of gender.
In our subsequent investigation [72], we have re-analyzed the
EBV lines described in the ﬁrst report, signiﬁcantly adding to the
sample with 38 new cell lines so that in the second investigation
for each proband both of their parents were now included in the
analysis. Cells in culture, or frozen lines were ﬁrst thawed, and then
cultured, and their CD38 mRNA levels measured. It was important
to determine whether expression of CD38 is stable and is main-
tained despite repeated cycles of freezing and thawing. The new re-
sults conﬁrm that CD38 expression in ASD patient lines is
substantially lower than in those derived from the patients’ parents
(Fig. 2). Although these results are not a fully independent replica-
tion, we believe they nevertheless considerably strengthen our ﬁrst
ﬁndings that reduced CD38 transcription is a characteristic of
peripheral lymphocyte cells derived from ASD subjects [69] (see
Fig. 2).
The surface expression of CD38 on blood cells varies signiﬁ-
cantly throughout the life course. Normally, expression is high on
cord blood cells and diminishes in cells obtained from adults
[71]. Hence the age difference between ASD subjects and their par-
ents could be a confounding factor in interpretation of our results.
However, no age-related differences indexed by mRNA levels were
observed in LBC lines obtained from the ASD patient group or fromFig. 1. Distribution of the expression (log transformed) of the CD38 gene as
depicted in a (A) scatter plot and (B) box plot. Lower expression in the ASD group is
signiﬁcant (p = 0.003). Taken from [69].
Fig. 2. The effect of 48 h 0.1 lm ATRA treatment on CD38 mRNA levels in LBC lines.
HH, independent samples t-test, t = 3.199, p = 0.002; prolonged ATRA treatment
elevates reduced CD38 mRNA levels in LBC lines from ASD patients (N = 42) above
parental (P) basal expression (N = 78). Also, basal and induced CD38 mRNA levels
are signiﬁcantly reduced in ASD cell lines compared to parental (P) cell lines (⁄⁄⁄,
independent t-test; p < 0.001). Taken from [72].
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using immortalized cell lines [69,72].
10. Retinoids
Retinoids are a class of compounds consisting of retinol (vita-
min A) and its derivatives and synthetic analogs [73,74]. Natural
retinoids are fundamental for many physiologic processes, such
as reproduction, growth, and cellular differentiation. These effects
are mediated by binding to and activating two different types of
nuclear receptors, the retinoic acid (RA) receptors (RARs) and reti-
noid X receptors (RXRs). All-trans-RA (ATRA) is a high-afﬁnity li-
gand for RARs only, whereas 9-cis-RA is a high-afﬁnity ligand for
both RARs and RXRs. RAR-RXR heterodimers activate the transcrip-
tion of target genes in response to ATRA or 9-cis-RA, whereas RXR–
RXR homodimers transactivate in response to 9-cis-RA.
11. Retinoids and CD38
all-trans retinoic acid (ATRA) is a potent inducer of CD38 [75]
suggesting the possibility that this compound can be used to ‘res-
cue’ cells exhibiting low CD38 synthesis and hence might be a no-
vel therapeutic strategy in treatment of autism.
In human promyelocytic leukemia HL-60 cells the expression of
CD38 mRNA by RA appeared to be caused by the transcriptional
stimulation of the gene, since it was blocked by an RNA synthesis
inhibitor, but not by a protein synthesis inhibitor [76]. Transient
transfection experiments revealed that the responsiveness to RA
was conferred through a RARE (retinoic acid responsive element)
consisting of two direct repeat TGACCT-like hexamer motifs with
a 5-nucleotide spacer, which was located in the ﬁrst intron rather
than the 5-ﬂanking region of the CD38 gene. This RARE interacted
with heterodimer composed of RA receptor and retinoid X receptor
in vitro. Thus, the RA-induced expression of the human CD38 gene
was demonstrated to be mediated through the RARE located in the
ﬁrst intron.
12. In vitro rescue by retinoids of CD38 deﬁciency in autism [72]
We wanted to determine whether the diminished expression of
CD38 in ASD could be reversed through simple treatment withATRA. Such a demonstration would provide in vitro ‘proof of prin-
ciple’ that retinoids could play a role in the clinical treatment of
ASD.
Following 48 hours of ATRA treatment, the results indicate that
the CD38 gene in the EBV lines obtained from the ASD probands
conserves its ability to respond with a signiﬁcant induction of
CD38 mRNA (Fig. 2). The parental lines display the same ability,
although to a lesser extent (paired t test t = 13.26
p < 0.001 ± ATRA). These results, demonstrating that ATRA can ele-
vate CD38 levels in cells obtained from ASD subjects who show im-
paired CD38 transcription, strengthen the notion that vitamin A
and related retinoids are potential therapeutic agents in the treat-
ment of ASD. Indeed, retinoids are widely used as treatment mod-
ules in a spectrum of diseases including acne & psoriasis [77],
cancer [78] and as a dietary supplement reduces child mortality
between 6 months to ﬁve years in low and middle income coun-
tries [79]. We put forward the prospect that retinoids are potential
therapeutic agents in autism and possibly other disorders that are
characterized by dysfunctional social cognition/relationships espe-
cially where oxytocin has been suggested to play a role.
There is a longstanding notion that vitamin A plays a role in
psychiatric illness [80] likely based on the profound effects of ret-
inoids on brain development and processes such as long-term
potentiation (LTP) and mood regulation [81]. Interestingly, during
early development mice pass through a narrow post-natal window
where they are very sensitive to brief exposure to retinoic acids.
Such exposures have signiﬁcant long-term behavioral effects
[82], Interestingly, retinoid-induced abnormalities appear to be
due to damage to the limbic system, a brain area that plays a cru-
cial role in a number of behavioral pathologies. Furthermore, these
post-natal effects of experimental retinoid manipulations incur
minimal anatomical changes (in comparison to manipulations dur-
ing the prenatal period) whereas behavioral effects are quite pro-
found. Intriguingly, the cortex of retinoic acid deprived rats is
characterized by beta-amyloid accumulation and other changes
that parallel those in Alzheimer’ disease [83]. Additionally, normal
memory loss in aging rats can be alleviated by vitamin A therapy
[84]. In the adult hippocampus, retinoids are essential for the
maintenance of synaptic plasticity including LTP and neurogenesis
[85], The hippocampus is a brain region dependent upon neural
plasticity for its function in learning and memory, Altogether, this
brief summary of a very extensive literature on retinoids and the
brain ﬁrstly provides a perspective for interpreting our investiga-
tion [72] that CD38 transcription is correlated with cognitive func-
tion in ASD and secondly, that retinoids are potential therapeutic
agents in autism.13. CD38 genotype and ATRA response
Cell lines were genotyped for the rs6449182 SNP, which leads to
a C?G variation. This SNP is located in intron 1 of the regulatory
region of human CD38, proximal to RARE. The presence of the al-
lele G is reported as being paralleled by increased binding of the
transcription factor E2A [86]. Furthermore, the G allele marks an
increased risk in CLL patients of transformation into Richter’s syn-
drome [87].
The results from our second study [72], indicate that the pres-
ence of the G allele is paralleled by (i) reduced transcriptional lev-
els of CD38 mRNA, a characteristic shared by ASD with those of the
parental lines although in LBC lines obtained from ASD probands
the difference does not attain statistical signiﬁcance. Furthermore,
(ii) the G allele is accompanied by reduced sensitivity to ATRA
treatment (+ ATRA treatment in parental lines CC = 0.82 ± 0.04;
CG = 0.69 ± 0.04 p = 0.04).
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the ASD sample
Our results showing that CD38 expression is reduced in ASD
prompted us to examine whether its expression levels might also
reﬂect phenotypical characteristics of ASD further enhancing the
value of this ectoenzyme as a potential biomarker. We looked at
social functioning measures that were available for these probands
since such deﬁcits are a core clinical characteristic of autism. The
results obtained clearly show a signiﬁcant correlation between
transcriptional levels of CD38 mRNA and IQ and Vineland Adaptive
Behavioral Scores (VABS) scores [88], except for VABS socialization.
Nonetheless, the correlation with the VABS total scores does prove
signiﬁcant (r = 0.431, p = 0.008, N = 42).
CD38 mediates oxytocin brain release [59] and importantly,
oxytocin itself enhances social learning and memory in the lim-
bic system [89]. If retinoids modulate CD38 transcription in the
brain, which in turn mediates oxytocin release, then the relation-
ship we have shown [72] between cognitive function and CD38
mRNA levels in LBC cells may be reﬂecting common state char-
acteristics of OT-CD38-RA pathways in different tissues. Indeed,
various studies have employed LBC lines to model brain dysfunc-
tions in autism [90–92] and other neuropsychiatric disorders
[93–97].
Finally, it needs to be noted that the potential use of retinoids in
any therapeutic intervention must be tempered with the evidence
that too high exposure to retinoids is as harmful as too little.
15. Biomarkers for autism spectrum disorders
Despite the considerable part that heredity plays in the etiology
of ASD the identiﬁcation of which speciﬁc genes, and how many
genes, contribute to ASD remains a challenge. For example, a recent
GWAS study [98] genotyped 1558 families and only a single marker
attained genome-wide signiﬁcance. Exploratory analysis of pheno-
type subtypes yielded some promising candidate genes, which did
not survive correction formultiple testing. To date, only rare denovo
mutations are validated genetic risk factors for ASD and most other
ﬁndings from GWAS and association studies need to be considered
provisional. However, such rare variants, although they might offer
important clues to the underlying pathophysiology and brain bio-
chemistry in autism, only account for a small proportion of the total
genetic risk. Some chromosomal rearrangements appear causal,
with the most common being maternal duplicationof 15q11–q13
[99]. Rare de novo mutations of high penetrancefor ASD have been
identiﬁed in synaptic genes, includingNLGN3,NLGN4XandSHANK3
[100–102]. Similar to other neuropsychiatric disorders copynumber
variations (CNV) also contribute overall risk to ASD [103] including
rare deletion CNVs of SHANK3 and the surrounding 22q13.33 region
found in individuals with ASD [103].
The current observation that CD38 expression is reduced in
lymphoblastoid cells derived from ASD subjects suggests the
prospect that CD38 might be an early hallmark for this disorder.
As noted by Yirmiya and Charman [104] ‘‘the primary motivation
for identifying the earliest signs of emerging ASDs is the desire to
develop and test early or even ‘preventative’ interventions to
lessen morbidity by changing the course of early emerging
developmental perturbation, thus preventing ‘secondary’ neuro-
developmental disturbances.’’ Towards evaluating the potential
of CD38 as a hallmark in ASD, reduced CD38 expression needs
ﬁrstly to be veriﬁed in circulating lymphocytes. Secondly, it must
be stressed that CD38 transcription is a marker for other diseases.
It is prognostic for HIV infected subjects [105], chronic lymphoid
leukemia [106] and for diabetic patients with nephropathy [107].
Hence reduced CD38 transcription cannot be pathognomonic forASD but nevertheless might prove of salient clinical value in a
disorder diagnosed solely using behavioral assessments reliably
carried out only at the age of three [104]. Moreover, CD38 expres-
sion changes throughout the lifespan [71] and age-dependent
CD38 expression in circulating lymphocytes are potential con-
founds in its use as a diagnostic indicator in ASD. However, the
critical need in ASD is for very early (prenatal or perinatal) diag-
nostic tools and, hence from this perspective, CD38 mRNA levels
in cord blood or amniotic ﬂuid might be of substantial value not-
withstanding subsequent age-related changes in lymphocyte
CD38 expression.
One group of biomarkers for neuropsychiatric disorders that
shows considerable promise is blood gene expression proﬁling
[108–113]. Most of the studies to date have focused on human
lymphocytes gene expression proﬁling, comparison between ill-
ness groups and normal controls, and cross-matching with human
postmortem brain gene expression data. A number of studies have
speciﬁcally examined gene expression patterns in ASD [90–
92,114–123]. It should be noted that predating this gush of expres-
sion studies in ASD, hyperserotonemia was observed in one third of
patients and platelet serotonin was suggested as a marker for this
disorder [124–127].
To summarize, the difﬁculty to validate speciﬁc gene variants
for most cases of autism likely reﬂects a variety of causes includ-
ing gene x gene interactions, the heterogeneous nature of this
disorder, and epigenetic modiﬁcations due to diverse environ-
mental challenges. The challenge of ﬁnding speciﬁc genes con-
tributing to ASD, except in those rare cases and their families
showing Mendelian inheritance, suggests that complementary
strategies to supplement more standard molecular genetic asso-
ciation studies would be worthwhile. Such an approach has been
proposed by Le-Niculescu and his colleagues [128]. Their ap-
proach, termed convergent functional genomics (CFG), which
translationally cross-matches animal model gene expression data
with human genetic data and human tissue data (blood, post-
mortem brain), as a Bayesian strategy of cross-validating ﬁnd-
ings, reducing the false positives and false negatives inherent
in each individual approach, and helping identify true candidate
genes, pathways and mechanisms for neuropsychiatric disorders.16. Conclusion
The current study adds to the growing list of potential biomark-
ers in ASD and moreover, uniquely observes a correlation between
expression levels of CD38 in LBC derived from these subjects and
social and communication skills that are core deﬁcits in this disor-
der. Notably, the potential of CD38 expression as a diagnostic indi-
cator for ASD was a hypothesis driven idea catalyzed by the
seminal study of Higashida and his colleagues [59] in the CD38
knockout mouse and reinforced by two independent molecular ge-
netic studies showing association between SNPs in the CD38 gene
and ASD [68,69].
In addition to the potential of CD38 as a hallmark that may
prove useful in early diagnosis of illness, the study of CD38 expres-
sion in peripheral lymphocytes has allowed us to model the poten-
tial of retinoic acids as a therapeutic agent in ASD. Indeed, we have
shown that LBC derived from ASD subjects and characterized by re-
duced CD38 transcription can be ‘rescued’ by simple treatment
with all-trans retinoic acid. We believe these results provide the
ﬁrst ‘proof of principle’ for a novel therapeutic strategy in treat-
ment of ASD by enhancing OT secretion in the brain indirectly by
ATRA induction of CD38 followed by mobilization of ryanodine-
sensitive intracellular Ca2+ stores from the endoplasmic reticulum
which in turn release OT.
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